Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment

Rawson, T; Charani, E; Moore, L; Herrero, P; Baik, J; Philip, A; Gilchrist, M; Brannigan, E; Georgiou, P; Hope, W; Holmes, A

doi:https://www.dx.doi.org/10.1016/j.jinf.2016.12.011

File(s)

Vancomycin_V7.0_JI_lte.docx (433.06 KB)

Accepted version

Author(s)

Rawson, T

Charani, E

Moore, L

Herrero, P

Baik, J

more

Type

Journal Article

Date Issued

2016-12-30

Date Acceptance

2016-12-30

Citation

Journal of Infection, 2016, 74 (3), pp.320-324

URI

http://hdl.handle.net/10044/1/43599

DOI

https://www.dx.doi.org/10.1016/j.jinf.2016.12.011

ISSN

1532-2742

Publisher

Elsevier

Start Page

320

End Page

324

Journal / Book Title

Journal of Infection

Volume

74

Issue

3

Copyright Statement

© 2016 The British Infection Association. Published by Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Sponsor

National Institute for Health Research

Grant Number

HPRU-2012-10047

II-LA-0214-20008

Subjects

Antimicrobial resistance

Obesity

Pharmacokinetic–pharmacodynamic

Population modelling

Vancomycin

Microbiology

1103 Clinical Sciences

Publication Status

Published